Literature DB >> 28000430

Metabolites distinguishing visceral fat obesity and atherogenic traits in individuals with overweight.

Seung Han Baek1, Minkyung Kim2, Minjoo Kim2, Miso Kang3,4, Hye Jin Yoo3,4, Nan Hee Lee3,4, Yong Hwan Kim5, Min Song5, Jong Ho Lee2,3,4.   

Abstract

OBJECTIVE: To screen the metabolomes of both overweight subjects with low visceral fat area (LFO) and high visceral fat area (HFO) to identify potential metabolites that are associated with the different metabolic characteristics.
METHODS: The metabolic characteristics of 112 overweight (25 kg/m2  ≤ BMI < 30 kg/m2 ) Korean individuals aged 30 to 65 years were examined. Plasma metabolomic profiling of HFO [visceral fat area (VFA) at L4 ≥ 100 cm2 ] and LFO (L4 VFA <100 cm2 ) individuals matched for age, gender, and BMI was performed.
RESULTS: HFO subjects showed higher VFA at L1 and L4 than LFO subjects. The HFO group showed higher blood pressure, lipid profile, high-sensitivity C-reactive protein, malondialdehyde, oxidized low-density lipoprotein (LDL), and homeostasis model assessment-insulin resistance and lower high-density lipoprotein-cholesterol levels. In plasma metabolite identification, the HFO group showed significantly higher levels of long-chain (C14:1, C16:1, C16) acylcarnitines (ACs), medium-chain (C12:1, C12) ACs, urobilinogen, docosahexaenoic acid (C22:6ω3), lysoPE (22:6), lysoPC (22:6), lysoPC (22:5), methoxybenzenepropanoic acid, and isodesmosine. All five ACs correlated positively with VFA and oxidized LDL levels and negatively with high-density lipoprotein-cholesterol levels and LDL particle size.
CONCLUSIONS: Twelve major metabolites, including three long-chain fatty acids and two medium-chain ACs, are important for distinguishing HFO and LFO. Chronic lipid surplus from visceral fat in HFO is likely associated with substantial increases in plasma medium-chain ACs and long-chain fatty acids, which are closely related to atherogenic traits.
© 2016 The Obesity Society.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28000430     DOI: 10.1002/oby.21724

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  8 in total

Review 1.  Metabolomics prospect of obesity and metabolic syndrome; a systematic review.

Authors:  Moloud Payab; Akram Tayanloo-Beik; Khadijeh Falahzadeh; Maryamossadat Mousavi; Saeede Salehi; Shirin Djalalinia; Mahbube Ebrahimpur; Nafiseh Rezaei; Mostafa Rezaei-Tavirani; Bagher Larijani; Babak Arjmand; Kambiz Gilany
Journal:  J Diabetes Metab Disord       Date:  2021-11-26

2.  Metabolomics identifies increases in the acylcarnitine profiles in the plasma of overweight subjects in response to mild weight loss: a randomized, controlled design study.

Authors:  Miso Kang; Hye Jin Yoo; Minjoo Kim; Minkyung Kim; Jong Ho Lee
Journal:  Lipids Health Dis       Date:  2018-10-15       Impact factor: 3.876

3.  Metabolomic Salivary Signature of Pediatric Obesity Related Liver Disease and Metabolic Syndrome.

Authors:  Jacopo Troisi; Federica Belmonte; Antonella Bisogno; Luca Pierri; Angelo Colucci; Giovanni Scala; Pierpaolo Cavallo; Claudia Mandato; Antonella Di Nuzzi; Laura Di Michele; Anna Pia Delli Bovi; Salvatore Guercio Nuzio; Pietro Vajro
Journal:  Nutrients       Date:  2019-01-26       Impact factor: 5.717

4.  A Metabolomics Analysis of Adiposity and Advanced Prostate Cancer Risk in the Health Professionals Follow-Up Study.

Authors:  Barbra A Dickerman; Ericka M Ebot; Brian C Healy; Kathryn M Wilson; A Heather Eliassen; Alberto Ascherio; Claire H Pernar; Oana A Zeleznik; Matthew G Vander Heiden; Clary B Clish; Edward Giovannucci; Lorelei A Mucci
Journal:  Metabolites       Date:  2020-03-10

5.  The Characteristics Of Abdominal Fat Distribution In Japanese Adolescents With Type 2 Diabetes Mellitus.

Authors:  Yuriko Abe; Tatsuhiko Urakami; Mitsuhiko Hara; Kei Yoshida; Yusuke Mine; Masako Aoki; Junichi Suzuki; Emiko Saito; Yayoi Yoshino; Fujihiko Iwata; Tomoo Okada; Ichiro Morioka
Journal:  Diabetes Metab Syndr Obes       Date:  2019-11-01       Impact factor: 3.168

6.  Multicohort Metabolomics Analysis Discloses 9-Decenoylcarnitine to Be Associated With Incident Atrial Fibrillation.

Authors:  Lars Lind; Samira Salihovic; Johan Sundström; Corey D Broeckling; Patrik K Magnusson; Jessica Prenni; Tove Fall; Johan Ärnlöv
Journal:  J Am Heart Assoc       Date:  2021-01-05       Impact factor: 5.501

7.  Metabolic Impairment in Coronary Artery Disease: Elevated Serum Acylcarnitines Under the Spotlights.

Authors:  Joséphine Gander; Justin Carrard; Hector Gallart-Ayala; Rébecca Borreggine; Tony Teav; Denis Infanger; Flora Colledge; Lukas Streese; Jonathan Wagner; Christopher Klenk; Gilles Nève; Raphael Knaier; Henner Hanssen; Arno Schmidt-Trucksäss; Julijana Ivanisevic
Journal:  Front Cardiovasc Med       Date:  2021-12-16

8.  The Plasma Metabolomic Profile is Differently Associated with Liver Fat, Visceral Adipose Tissue, and Pancreatic Fat.

Authors:  Lars Lind; Samira Salihovic; Ulf Risérus; Joel Kullberg; Lars Johansson; Håkan Ahlström; Jan W Eriksson; Jan Oscarsson
Journal:  J Clin Endocrinol Metab       Date:  2021-01-01       Impact factor: 5.958

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.